Alphabet’s SpaceX Investment Soars 100-Fold to $94 Billion 
Paramount Weighs CNN Sale as $110B Warner Bros. Discovery Deal Faces Antitrust Fight 
Tesla Roadster Reveal Could Feature SpaceX Thrusters in August 
Antofagasta Shares Drop 5% as Miner Cuts 2026 Copper Production Forecast 
SpaceX Shares Surge as Wall Street Backs AI Growth Potential 
Lenovo Revenue Surges 43% as AI Demand Drives Record First-Quarter Growth 
SMIC Shares Rally as Q2 Profit Surges 262% on Strong Chip Demand 
Apple Develops China-Specific AI Model With Alibaba as Apple Intelligence Launch Nears 
Aviva First-Half Operating Profit Jumps 24% as Direct Line Deal Boosts Growth 
Bank of America to Buy Up to 49.9% Stake in Jio Credit for $1.92 Billion 
Paramount Skydance Clears Regulatory Hurdles for Warner Bros. Discovery Deal 
Ford to Move Some Lincoln Production From China to U.S. in 2030 
Maersk Raises 2026 Earnings Outlook as Shipping Profits Beat Expectations 
Super Micro Stock Jumps 19% as AI Server Demand Drives Strong 2027 Outlook 
Pandora Shares Rise as Q2 Results Beat Forecasts, 2026 Outlook Raised 
Bill Ackman’s Pershing Square Returns to Netflix With Major New Stake 
Australia’s Corporate Leaders Face Parliament Over KPMG Client Data Scandal 
Add as a preferred source on Google
GSK plc, a pharmaceutical industry company, has entered into an agreement that will give it exclusive rights to Johnson & Johnson’s hepatitis B therapy, known as JNJ-3989. To secure this license, the firm is paying $1 billion to J&J.
The exclusive license will give GSK the rights to further develop and commercialize J&J’s hepatitis B drug. The therapy, which is currently in development, was initially developed by Arrowhead Pharmaceuticals and licensed to J&J’s Janssen unit in 2018, as per Reuters.
Expansion of GSK’s bepirovirsen Treatment
GSK’s rights to the JNJ-3989 therapy will give a boost to the expansion of its own hepatitis B treatment called the bepirovirsen, which is already in the last phase of development. The disease reportedly affects around 300 million people worldwide. It is a life-threatening infection of the liver, and patients can develop cirrhosis and liver cancer that can lead to death.
With the agreement with Johnson & Johnson for its JNJ-3989 treatment, GSK will be able to expand and complete the development of bepirovirsen. Under the terms of the deal, the British pharma and biotech company will pay a total of $1 billion in either upfront or milestone payment arrangements to both Arrowhead and Janssen.
Arrowhead Gains New Partner for the Hepatitis B Therapy
Since Johnson &Johnson sold the rights to JNJ-3989 to GSK, the latter will eventually become the new partner of the therapy’s original developer, Arrowhead. Then again, Janssen will continue to handle the ongoing clinical trials of JNJ-3989, which is now in phase 2 testing.
“We are excited to build on promising results already demonstrated with bepirovirsen to investigate a novel sequential regimen with JNJ-3989,” GSK’s chief scientific officer, Tony Wood, said in a press release. “We believe this approach could redefine the treatment paradigm for chronic hepatitis B by helping even more patients achieve a functional cure.”
Arrowhead’s president and CEO, Chris Anzalone, Ph.D., also commented, “GSK has a global reach, a clear commitment to help those living with chronic hepatitis B, and a promising strategy for clinical studies designed to improve functional cure rates. We have great confidence in the team at GSK and look forward to seeing this program progress towards the goal of potentially helping the millions of patients with chronic hepatitis B worldwide without adequate treatment options.”
Photo by: GSK Media Library
